Uri Amit, Advanced Fellow in Gynecologic and GU Brachytherapy, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, shared a post on LinkedIn:
“Ten years, 27 patients, no recurrences: happy to share our long-term outcomes of single-session APBI with permanent breast seed implantation using palladium-103, now out in Brachytherapy.
In this prospective trial, we treated 27 patients with early-stage breast cancer at the University of Calgary, using a modified protocol adapted from the Sunnybrook approach.
At a median follow-up of 10 years:
- No local or distant recurrences, and no breast cancer deaths
- No grade 3 or higher toxicity
- Excellent or good cosmesis in at least 90% of evaluable patients through 5 years
It’s a small, single-institution trial, so the usual caveats apply. Still, it’s encouraging long-term data for single-session APBI in carefully selected patients with favourable early-stage disease.
Thanks to my co-authors Siraj Husain, Tyler Meyer, Michael Roumeliotis, Karen Long, and to the patients who took part.”
Title: Permanent low-dose-rate seed implantation as single-session partial breast irradiation: Long-term outcomes using a modified institutional protocol
Authors: Uri Amit, Tyler Meyer, Michael Roumeliotis, Karen Long, Siraj Husain
Read the Full Article on Brachytherapy.
You can also read: NRG-BR002: Metastasis-Directed Ablation Fails to Improve PFS or OS in Oligometastatic Breast Cancer
